Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
复制标题
无法切除肝转移的 MNET 患者切除原发肿瘤的系统评价
DOI：
10.18632/oncotarget.14156
复制
发表时间：
2017-03-07
期刊：
影响因子：
--
通讯作者：
Zhao H
中科院分区：
文献类型：
--
作者：
Guo J;Zhang Q;Bi X;Zhou J;Li Z;Huang Z;Zhang Y;Li M;Chen X;Hu X;Yihebali C;Liang J;Liu J;Zhao J;Cai J;Zhao H
背景中肠神经内分泌肿瘤肝转移的治疗一直是一个有争议的问题。本系统综述旨在总结关于原发性肿瘤切除术在这组患者中的价值的现有证据。结果共纳入8个队列研究进行定性分析。没有一个严格符合纳入标准，无法进行荟萃分析。在所有8项研究中，原发性肿瘤切除组的总生存率有更好的趋势，其中6项研究显示出显著差异。在切除组中，肝脏疾病的无进展生存期延长，死于肝功能衰竭的患者较少。方法计算机检索MEDLINE、EMBASE和CENTRAL数据库，以总生存期为主要结局指标，无进展生存期、死亡原因和症状缓解为次要结局指标，检索至2016年7月4日。结论现有证据支持中肠神经内分泌肿瘤肝转移患者行原发灶切除术，但需要随机对照试验才能得出最终结论。
Background Treatment for midgut neuroendocrine tumor patients with unresectable liver metastasis has long been a controversial issue. This system review aims to summarize existing evidence concerning the value of primary tumor resection in this group of patients. Results 8 cohort studies were identified for qualitative analysis. None of them strictly met with the inclusion criteria and meta-analysis was impossible. There was a tendency towards better overall survival for the primary tumor resected group in all 8 studies, in which 6 demonstrated significant difference. Progression free survival to liver disease was prolonged and less patients died of liver failure in the resected group. Methods MEDLINE, EMBASE and CENTRAL were searched until 2016/7/4 for relevant studies, with primary outcome being overall survival, and secondary outcome being progression free survival, cause of death and symptom relief. Conclusions Current evidence supports resection of primary tumor for midgut neuroendocrine tumor patients with liver metastases, but randomized controlled trials are required to reach a final conclusion.